Market research
PBP.AU Probiotec Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 242M
- P/E ratio
- 29.8
- Analyst target
- 3
- Dividend yield
- 2.4%
- Beta
- 0.47
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- AU000000PBP7
- Market cap
- 242M
- P/E ratio
- 29.8
- Analyst target
- 3
- Dividend yield
- 2.4%
- Beta
- 0.47
About
About Probiotec Limited
Probiotec Limited engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coatings; blister packs, bottles, sachets, tubs, and tubes; liquids, creams, gels, lotions, ointments, and powders and powder blends. It is also involved in analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials. The company was incorporated in 1996 and is headquartered in Laverton North, Australia. As of June 18, 2024, Probiotec Limited operates as a subsidiary of PYFA Australia Pty Ltd.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PBP.AU discussion.
5 years, 5 months ago
Probiotec Limited is currently in a long term downtrend where the price is trading 2.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.4.
Probiotec Limited's total revenue sank by 3.5% to $43M since the same quarter in the previous year.
Its net income has increased by 79.1% to $1M since the same quarter in the previous year.
Finally, its free cash flow grew by 1252.5% to $3M since the same quarter in the previous year.
Based on the above factors, Probiotec Limited gets an overall score of 3/5.